Key result
Irbesartan/hydrochlorothiazide combination therapy achieved the target blood pressure goal in 57.3% of Chinese patients with moderate to severe hypertension after 12 weeks of treatment.
Why the study?
Does a fixed combination of irbesartan/hydrochlorothiazide improve blood pressure control in Chinese patients with moderate to severe hypertension?
Population
501 Chinese adults with moderate to severe hypertension, 52.7% female.
Design
Cohort, open-label
Follow-up
12 weeks
Authors
Loading...
May support BP control with irbesartan/HCTZ in Chinese patients; leaves open randomized confirmation.
Does a fixed combination of irbesartan/hydrochlorothiazide improve blood pressure control in Chinese patients with moderate to severe hypertension?
A fixed-dose combination of irbesartan and hydrochlorothiazide effectively lowered blood pressure to target levels in over half of Chinese patients with moderate to severe hypertension, with an acceptable safety profile.
Huang et al. (2013) studied Moderate to severe hypertension (n=501). Irbesartan/hydrochlorothiazide was evaluated on Goal blood pressure-attaining rate at 12 weeks of follow-up (<140/90 mmHg, or <130/80 mmHg in patients with diabetes mellitus). Irbesartan/hydrochlorothiazide combination therapy achieved the target blood pressure goal in 57.3% of Chinese patients with moderate to severe hypertension after 12 weeks of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: